TransMedics Group, Inc. (NASDAQ:TMDX) Shares Acquired by Principal Financial Group Inc.

Principal Financial Group Inc. boosted its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 2.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 198,427 shares of the company's stock after acquiring an additional 5,480 shares during the period. Principal Financial Group Inc. owned 0.59% of TransMedics Group worth $13,350,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Jones Financial Companies Lllp grew its stake in shares of TransMedics Group by 1,802.8% in the 4th quarter. Jones Financial Companies Lllp now owns 2,074 shares of the company's stock valued at $129,000 after buying an additional 1,965 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of TransMedics Group by 9.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 297,433 shares of the company's stock valued at $18,545,000 after buying an additional 25,739 shares during the period. Victory Capital Management Inc. grew its stake in shares of TransMedics Group by 76.3% in the 4th quarter. Victory Capital Management Inc. now owns 8,057 shares of the company's stock valued at $502,000 after buying an additional 3,488 shares during the period. Arizona State Retirement System grew its stake in shares of TransMedics Group by 1.9% in the 4th quarter. Arizona State Retirement System now owns 9,668 shares of the company's stock valued at $603,000 after buying an additional 184 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in shares of TransMedics Group in the 4th quarter valued at approximately $3,845,000. Hedge funds and other institutional investors own 99.67% of the company's stock.

Insider Transactions at TransMedics Group

In other news, insider Anil P. Ranganath sold 686 shares of the company's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the sale, the insider owned 13,955 shares of the company's stock, valued at approximately $1,950,909. This represents a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David Weill sold 732 shares of the company's stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $123.88, for a total value of $90,680.16. Following the sale, the director directly owned 12,134 shares in the company, valued at $1,503,159.92. This represents a 5.69% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,418 shares of company stock valued at $1,512,613. 7.00% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on TMDX. Canaccord Genuity Group increased their price target on shares of TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a research note on Tuesday. Piper Sandler restated an "overweight" rating and issued a $145.00 price objective (up from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a report on Tuesday, June 17th. Finally, Oppenheimer upped their price objective on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a report on Tuesday, June 17th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $129.88.

TransMedics Group Trading Down 2.0%

Shares of TMDX stock traded down $2.36 during trading hours on Wednesday, hitting $113.32. The company had a trading volume of 714,494 shares, compared to its average volume of 1,376,090. The company's fifty day moving average is $126.43 and its 200 day moving average is $91.41. The company has a debt-to-equity ratio of 1.92, a current ratio of 9.10 and a quick ratio of 8.32. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The stock has a market capitalization of $3.83 billion, a PE ratio of 83.32 and a beta of 2.06.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.29 by $0.41. TransMedics Group had a net margin of 10.03% and a return on equity of 21.88%. The company had revenue of $143.54 million during the quarter, compared to analysts' expectations of $123.39 million. During the same quarter last year, the company posted $0.35 EPS. The firm's revenue was up 48.2% compared to the same quarter last year. Research analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.